23andMe is exploring strategic alternatives, looking to raise capital
1. 23andMe explores strategic alternatives, including potential sale or restructuring. 2. The company faced an 82% stock value loss last year. 3. Revenue dropped 8% to $39.6 million in Q3. 4. 23andMe's market value fell below $100 million from $6 billion peak. 5. CEO Wojcicki's prior proposals to go private were rejected.